2025-10-29 10:08:02
Presenters: Lain E, Waibel J, Boyd C
Background: Photodamage is a prevalent dermatologic condition resulting from chronic ultraviolet (UV) exposure, leading to epidermal thinning, solar elastosis, fragmentation of dermal collagen and elastin fibers, and loss of hyaluronic acid (HA). These cumulative structural alterations contribute to compromised barrier function, reduced hydration, increased skin fragility, and the visible hallmarks of photoaging. Photodamage has been linked not only to aesthetic degradation but also to the development of inflammatory skin diseases and cutaneous malignancies. Despite the abundance of topical treatments available, few products demonstrate comprehensive clinical and molecular efficacy in reversing the damage induced by photoaging.
REGENX REJUVENATE SERUM is an advanced topical formulation that includes urodelederived collagen extract, a patented active shown in preclinical studies to stimulate extracellular matrix (ECM) remodeling by increasing HA, collagen, and elastin synthesis, while also modulating cutaneous inflammation.
Objective: This study aims to evaluate the efficacy, tolerability, and biological impact of twice-daily application of REGENX REJUVENATE SERUM over a 12-week period in subjects with moderate to severely photodamaged facial skin.
Methods: This prospective, open-label, multicenter clinical trial enrolled and completed 40 patients, male and female, aged 30 to 55 years, with Fitzpatrick Skin Types ranging from 1 to 6, across three geographically diverse U.S. sites including Birmingham, Michigan; Austin, Texas; and Miami, Florida. Participants discontinued their regular facial skincare regimens and used exclusively the sponsor-provided facial cleanser, moisturizer, sunscreen, and REGENX REJUVENATE SERUM. Subjects applied the serum twice daily to the entire face over a 12-week period. Inclusion criteria required that subjects exhibited mild to moderately severe signs of photodamage, including erythema, dryness or flaking, fine lines or wrinkles, and dyschromia.
The primary objective of the study was to evaluate improvements in clinical endpoints such as erythema, dryness, fine lines, dyschromia, and overall skin quality. Secondary assessments included expert visual grading of photodamage at baseline, week 4, week 8, and week 12; high-resolution Canfield Gen 5 VISIA CRP imaging at baseline and week 12; and standardized clinical photography captured from multiple facial angles at each visit. Subject-reported outcome measures were collected using validated questionnaires at baseline and on days 30, 60, and 90 to assess perceived improvements and product tolerability. Product usage and compliance were monitored throughout the study, with subject diaries reviewed at each timepoint. To complement the clinical data with histological analysis, seven subjects from three sites underwent preauricular 2-mm punch biopsies at baseline and again at week 12.
Results: Expert visual grading demonstrated clinically meaningful improvements across all evaluated parameters following 12 weeks of treatment with REGENX REJUVENATE SERUM. On a validated 0–5 ordinal scale (0 = none; 5 = severe), mean erythema scores decreased from 2.7 (mild–moderate) at baseline to 1.00 (minimal), dryness/flaking from 2.9 to 0.7, fine lines/wrinkles from 3.0 (moderate) to 1.4, and dyschromia from 3.2 to 1.7. Global improvement, assessed on a 0–4 scale (0 = none; 4 = marked), increased from a baseline score of 0 (none) to 2.7, indicating a transition toward moderate clinical benefit. These findings support the efficacy of REGENX REJUVENATE SERUM in improving key clinical manifestations of photodamaged skin.
©Matrix Medical Communications. View All Articles.